Brief: Celyad Doses First MCRC Patient In The Phase 1 AlloSHRINK Trial

Celyad Oncology SA

30/11/2018 06:07

Nov 30 (Reuters) - CELYAD SA  CYAD.BR :
    * CELYAD DOSES FIRST MCRC PATIENT IN THE PHASE 1 ALLOSHRINK
TRIAL
EVALUATING NON-GENE EDITED ALLOGENEIC CAR-T CANDIDATE, CYAD-101
    * COMPANY REGAINS FULL DEVELOPMENT AND COMMERCIALIZATION
RIGHTS TO
CYAD-101 FROM ONO PHARMACEUTICAL FOR JAPAN, KOREA AND TAIWAN
    * TOPLINE DATA FROM ALLOSHRINK TRIAL ARE EXPECTED IN SECOND
HALF
OF 2019
    * CELYAD CONTROLS WORLDWIDE DEVELOPMENT AND
COMMERCIALIZATION
RIGHTS TO CYAD-101

Source text for Eikon:  ID:nBw7pwNv1a 
Further company coverage:  CYAD.BR 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))